A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

This study has been completed.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00346957

Purpose

The purpose of the study was to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Condition	Intervention	Phase
AMD	Drug: anecortave acetate	Phase II

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Anecortave acetate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Mean change from baseline in logMAR visual acuity at month 12

Secondary Outcome Measures:

Secondary outcomes included the comparison of the Anecortave 30 mg and 3 mg dose groups to placebo and evaluation of results in the subgroup of patients with a predominantly classic CNV lesion at baseline

Estimated Enrollment:	128
Study Start Date:	April 1999

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ages 50 years and over

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00346957

Locations

United States, New York
Site
New York, New York, United States, 10021

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Patricia Zilliox

Alcon Research

More Information

Study ID Numbers:	C-98-03
Study First Received:	June 28, 2006
Last Updated:	June 30, 2006
ClinicalTrials.gov Identifier:	NCT00346957
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Eye Diseases
Retinal Degeneration
Macular Degeneration
Retinal Diseases
Retinal degeneration

ClinicalTrials.gov processed this record on January 14, 2009